CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis

Background: The mechanism underlying disease progression in progressive multiple sclerosis (MS) is uncertain. Pathological studies found widespread inflammation in progressive MS brains correlating with disease progression and axonal damage. Objectives: To study cerebrospinal fluid (CSF) biomarkers and clarify whether inflammation and axonal damage are associated in progressive MS. Methods: Using enzyme-linked immunosorbent assay (ELISA), we analysed CSF from 40 secondary progressive (SPMS), 21 primary progressive (PPMS), and 36 relapsing–remitting (RRMS) and 20 non-inflammatory neurological disease (NIND) patients. Twenty-two of the SPMS patients participated in an MBP8298 peptide clinical trial and had CSF follow-up after one year. Results: Compared to NIND patients, inflammatory biomarkers osteopontin and matrix metalloproteinase-9 (MMP9) were increased in all MS patients while CXCL13 was increased in RRMS and SPMS patients. Biomarkers of axonal damage (NFL) and demyelination (MBP) were increased in all MS patients. In progressive MS patients CSF levels of osteopontin and CXCL13 correlated with NFL while osteopontin and MMP9 correlated with MBP. MBP8298 treatment did not affect the levels of the biomarkers after one year of treatment. All biomarkers were continuously increased after one year of follow-up except MBP, which decreased. Conclusion: CSF biomarkers of inflammation, axonal damage and demyelination are continuously increased in progressive MS patients and correlate. These findings parallel pathology studies, emphasise a relationship between inflammation, axonal damage and demyelination and support the use of CSF biomarkers in progressive MS clinical trials.

[1]  H. Lassmann,et al.  Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. , 2000, The American journal of pathology.

[2]  S. McQuaid,et al.  Up‐regulation of osteopontin and αΒ‐crystallin in the normal‐appearing white matter of multiple sclerosis: an immunohistochemical study utilizing tissue microarrays , 2005, Neuropathology and applied neurobiology.

[3]  T. Olsson,et al.  Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab , 2011, Annals of neurology.

[4]  F. Barkhof,et al.  CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis , 2004, Neurology.

[5]  J. Newcombe,et al.  Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. , 2006, Brain : a journal of neurology.

[6]  C. Polman,et al.  Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[7]  David H. Miller,et al.  Primary-progressive multiple sclerosis , 2007, The Lancet Neurology.

[8]  M. Rovaris,et al.  Secondary progressive multiple sclerosis: current knowledge and future challenges , 2006, The Lancet Neurology.

[9]  L. Kappos,et al.  Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. , 1998, Brain : a journal of neurology.

[10]  A. Compston,et al.  Multiple sclerosis. , 2002, Lancet.

[11]  A. Traboulsee,et al.  A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS , 2011, Neurology.

[12]  Hans Lassmann,et al.  Cortical demyelination and diffuse white matter injury in multiple sclerosis. , 2005, Brain : a journal of neurology.

[13]  H. Lassmann,et al.  Progressive multiple sclerosis , 2009, Seminars in Immunopathology.

[14]  M. Christiansen,et al.  Cerebrospinal fluid measures of disease activity in patients with multiple sclerosis , 1998, Multiple sclerosis.

[15]  C. V. Jensen,et al.  Gadolinium-enhanced magnetic resonance imaging predicts response to methylprednisolone in multiple sclerosis , 2003, Multiple sclerosis.

[16]  H. Lassmann,et al.  The molecular basis of neurodegeneration in multiple sclerosis , 2011, FEBS letters.

[17]  Hristian,et al.  RELAPSES AND PROGRESSION OF DISABILITY IN MULTIPLE SCLEROSIS , 2000 .

[18]  G. Niepel,et al.  Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis. , 2008, Archives of neurology.

[19]  M Daumer,et al.  Age and disability accumulation in multiple sclerosis , 2011, Neurology.

[20]  B. Serafini,et al.  Detection of Ectopic B‐cell Follicles with Germinal Centers in the Meninges of Patients with Secondary Progressive Multiple Sclerosis , 2004, Brain pathology.

[21]  I. Bechmann,et al.  Perivascular Spaces and the Two Steps to Neuroinflammation , 2008, Journal of neuropathology and experimental neurology.

[22]  P. Sørensen,et al.  Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS , 2009, Neurology.

[23]  T. Olsson,et al.  Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis , 2003, Journal of Neuroimmunology.

[24]  Jorge R. Oksenberg,et al.  Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis , 2002, Nature Medicine.

[25]  P. Sørensen,et al.  Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis , 2011, Multiple sclerosis.

[26]  Jakob S. Jensen,et al.  Immunological effects of oral high‐dose methylprednisolone in acute optic neuritis and multiple sclerosis , 2000, European journal of neurology.

[27]  Hans Lassmann,et al.  The relation between inflammation and neurodegeneration in multiple sclerosis brains , 2009, Brain : a journal of neurology.

[28]  S. Youssef,et al.  Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells , 2007, Nature Immunology.

[29]  Hans Lassmann,et al.  Widespread Demyelination in the Cerebellar Cortex in Multiple Sclerosis , 2007, Brain pathology.

[30]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[31]  L. Kappos,et al.  The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. , 2001, Brain : a journal of neurology.

[32]  R. Reynolds,et al.  Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. , 2011, Brain : a journal of neurology.

[33]  L. Rosengren,et al.  Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS , 2003, Neurology.

[34]  B. Uitdehaag,et al.  The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[35]  T. Olsson,et al.  The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment‐sensitive biomarkers , 2009, European journal of neurology.